JP5139058B2 - 新形成または新生脈管構造の検出、画像化および処置のための血管標的 - Google Patents

新形成または新生脈管構造の検出、画像化および処置のための血管標的 Download PDF

Info

Publication number
JP5139058B2
JP5139058B2 JP2007515574A JP2007515574A JP5139058B2 JP 5139058 B2 JP5139058 B2 JP 5139058B2 JP 2007515574 A JP2007515574 A JP 2007515574A JP 2007515574 A JP2007515574 A JP 2007515574A JP 5139058 B2 JP5139058 B2 JP 5139058B2
Authority
JP
Japan
Prior art keywords
annexin
agent
imaging
neovasculature
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007515574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501701A5 (https=
JP2008501701A (ja
Inventor
シュニッツァー，ジャン，イー．
オー，フィリップ
Original Assignee
シドニー キンメル キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シドニー キンメル キャンサー センター filed Critical シドニー キンメル キャンサー センター
Publication of JP2008501701A publication Critical patent/JP2008501701A/ja
Publication of JP2008501701A5 publication Critical patent/JP2008501701A5/ja
Application granted granted Critical
Publication of JP5139058B2 publication Critical patent/JP5139058B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2007515574A 2004-06-02 2005-06-02 新形成または新生脈管構造の検出、画像化および処置のための血管標的 Expired - Fee Related JP5139058B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57611604P 2004-06-02 2004-06-02
US60/576,116 2004-06-02
PCT/US2005/019399 WO2005117848A2 (en) 2004-06-02 2005-06-02 Vascular targets for detecting, imaging and treating neoplasia or neovasculature

Publications (3)

Publication Number Publication Date
JP2008501701A JP2008501701A (ja) 2008-01-24
JP2008501701A5 JP2008501701A5 (https=) 2008-07-17
JP5139058B2 true JP5139058B2 (ja) 2013-02-06

Family

ID=35463318

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515574A Expired - Fee Related JP5139058B2 (ja) 2004-06-02 2005-06-02 新形成または新生脈管構造の検出、画像化および処置のための血管標的

Country Status (7)

Country Link
US (2) US20060024315A1 (https=)
EP (1) EP1755646A2 (https=)
JP (1) JP5139058B2 (https=)
AU (1) AU2005249541B2 (https=)
CA (1) CA2572451C (https=)
TW (1) TWI445525B (https=)
WO (1) WO2005117848A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130525A2 (en) * 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
NZ569078A (en) * 2005-12-12 2012-01-12 Mosamedix Bv Annexin derivatives suitable for pretargeting in therapy and diagnosis
AU2007284651B2 (en) * 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
EP2370055A2 (en) * 2008-11-30 2011-10-05 University Of The Witwatersrand, Johannesburg Polymeric pharmaceutical dosage form in sustained release
GB0822011D0 (en) 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
TWI387750B (zh) * 2009-02-10 2013-03-01 Nat Defense Medical Ct Biomarker and detection method for detecting kidney disease
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
EP2580241B1 (en) * 2010-06-09 2020-11-04 Queen Mary & Westfield College, University of London Annexin 1 antibody
WO2012051556A1 (en) * 2010-10-15 2012-04-19 Duke University Compositions and methods for the treatment of cardiac surgery-associated acute kidney injury with annexin a1 peptide
EP2691120A4 (en) * 2011-03-31 2014-09-24 Univ Johns Hopkins THEROSTATIC ILLUSTRATION AND USE METHOD THEREFOR
CN102898527B (zh) * 2011-07-25 2016-12-21 三星电子株式会社 融合蛋白、药物组合物及预防或治疗癌症的方法
GB201121564D0 (en) 2011-12-14 2012-01-25 Queen Mary & Westfield College Use of antibody
US10172915B2 (en) 2013-10-20 2019-01-08 Duke University Methods and compositions for activation of sirtuins with Annexin A1 peptides
GB201702091D0 (en) 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules
WO2018226971A1 (en) * 2017-06-07 2018-12-13 Cedars-Sinai Medical Center Peptide compositions for immuno-oncology molecular imaging and targeted drug delivery
GB201813137D0 (en) 2018-08-10 2018-09-26 Medannex Ltd Cancer treatment with an antibody
GB202019109D0 (en) * 2020-12-03 2021-01-20 Novai Ltd Marker for use in identifying or predicting angiogenesis

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5314992A (en) * 1991-11-25 1994-05-24 Trustees Of Dartmouth College Lipocortin-1 receptor protein and its uses
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US6358915B1 (en) * 1995-03-07 2002-03-19 George Washington University Methods for inhibiting metastasis
US6180596B1 (en) 1995-05-18 2001-01-30 Wisconsin Alumni Research Foundation Methods of inhibiting phospholipase A2 and phospholipase A2 stimulator activities
US5658877A (en) * 1995-05-18 1997-08-19 Wisconsin Alumni Research Foundation Method to treat endotoxin effects by administration of 33 kilodalton phospholipid binding protein
US20030008819A1 (en) 1995-09-08 2003-01-09 Schnitzer Jan E. Targeting endothelium for tissue-specific delivery of agents
EP0848614B1 (en) 1995-09-08 2006-04-26 Beth Israel Deaconess Medical Center Isolation of microdomains of caveolae and gpi-anchored proteins
US20040115128A1 (en) 1995-09-08 2004-06-17 Schnitzer Jan E. Targeting endothelium for tissue-specific delivery of agents
DE69821932T2 (de) 1997-05-30 2004-12-16 Arch Development Corp., Chicago P-selectin translokation ins vaskulare epitheliale lumen durch ionisierende strahlung
JP2001516055A (ja) 1997-09-10 2001-09-25 ザ バーナム インスティチュート 腫瘍中の血管形成血管系にホーミングする分子を同定する方法
CA2219299A1 (en) * 1997-10-24 1999-04-24 Elias Georges P-40, a new member of the multidrug resistance gene family
US7067109B1 (en) 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
CA2333147C (en) 1998-07-13 2012-02-07 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1157274A1 (en) 1999-03-02 2001-11-28 The University of Dundee Methods of determining altered ndpk functions
AU5472200A (en) 1999-06-17 2001-01-09 Regeneron Pharmaceuticals, Inc. Methods of imaging and targeting tumor vasculature
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
DE10017249A1 (de) * 2000-04-06 2001-10-11 Peter Solisch In-Vitro-Verfahren zur Feststellung bösartiger Tumore in der Human- und Veterinärmedizin
JP2004510830A (ja) 2000-10-11 2004-04-08 ターゲサム・インコーポレーテッド 標的化された治療用薬剤
AU2002217760A1 (en) 2000-10-12 2002-04-22 The University Of Tennessee Research Corporation Targeting drug/gene carriers to irradiated tissue
WO2002076394A2 (en) 2001-03-22 2002-10-03 The Ohio State University Research Foundation Enzyme-based anti-cancer compositions and methods
CA2443314C (en) 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
US7666391B2 (en) 2001-06-01 2010-02-23 Burnham Institute For Medical Research Breast homing peptides and methods of identifying same using aminopeptidase P
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US6531655B2 (en) * 2001-06-27 2003-03-11 Stuete Schaltgerate Gmbh & Co. Kg Protective-door handle
US20030162706A1 (en) * 2002-02-08 2003-08-28 The Procter & Gamble Company Angiogenesis modulating proteins
EP1646357A4 (en) 2003-06-27 2007-01-10 Diadexus Inc PRO104 ANTIBODY COMPOSITIONS AND APPLICATION PROCEDURES
WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
WO2005027965A1 (en) * 2003-09-24 2005-03-31 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
WO2005094882A1 (en) 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
EP1755686A2 (en) 2004-06-02 2007-02-28 Sidney Kimmel Cancer Center Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface

Also Published As

Publication number Publication date
WO2005117848A9 (en) 2006-04-27
CA2572451A1 (en) 2005-12-15
WO2005117848A2 (en) 2005-12-15
AU2005249541A1 (en) 2005-12-15
US8715675B2 (en) 2014-05-06
US20110044893A1 (en) 2011-02-24
WO2005117848A3 (en) 2006-06-29
CA2572451C (en) 2016-05-10
AU2005249541B2 (en) 2010-02-25
TW200602081A (en) 2006-01-16
JP2008501701A (ja) 2008-01-24
EP1755646A2 (en) 2007-02-28
US20060024315A1 (en) 2006-02-02
TWI445525B (zh) 2014-07-21

Similar Documents

Publication Publication Date Title
US8715675B2 (en) Vascular targets for detecting, imaging and treating neoplasia or neovasculature
US6689744B2 (en) Notch receptor agonists and uses
JP4347694B2 (ja) 癌関連抗原ｃｄ４６に結合する抗体およびその使用方法
CN114929278A (zh) 抗ccr8抗体及其用途
TWI409078B (zh) 靶定表現於肺內皮細胞表面之蛋白質的組織專一性成像和治療劑
US20180094054A1 (en) Antibodies that bind cell surface grp78 and their use for detection of cancer
JP6908964B2 (ja) Ｐｓｍａリガンドコンジュゲートによる併用療法
JP5847755B2 (ja) 細胞を検出する方法、およびこれに有用な薬剤
TW201130512A (en) Methods for the treatment of head and neck squamous cell carcinoma
US9028818B2 (en) Antibodies binding to adrenomedullin receptors and uses thereof as drugs
JP2020518639A (ja) 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
CN109863402A (zh) 基于β2-糖蛋白1水平的用巴维昔单抗治疗癌症的方法和其测定
AU2005249553B2 (en) Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
JP4365583B2 (ja) ノッチレセプターアゴニスト及び用途
KR102783861B1 (ko) 인간화 항 psa(5a10) 항체
US20050260132A1 (en) Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
EP4497755A1 (en) Anti-wnt-11 antibodies
EP3886913A1 (en) Enhanced targeted delivery of therapeutic agents
AU2003302733A1 (en) Methods of therapy and diagnosis using targeting of cells that express LAX
US20050129697A1 (en) Methods of therapy and diagnosis using targeting of cells that express BCLP polypeptides
WO2017062394A1 (en) Intraductal delivery of targeted alpha-particle, beta-particle or auger electron-emitters for treatment of breast cancer
CA2561192A1 (en) Cancerous disease modifying antibodies
WO2004094607A2 (en) Methods of therapy and diagnosis using targeting of cells that express a human transporter-like protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111006

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120919

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121108

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121115

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5139058

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151122

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees